lirentelimab (AK002) - Allakos
ligelizumab (QGE 031) - Novartis
Cinqair (reslizumab) - Merck (MSD), UCB, Teva
Xolair (omalizumab) - Roche, Novartis
LY3454738 - Eli Lilly
tezepelumab (AMG 157) - AstraZeneca, Amgen
Cosentyx (secukinumab) - Novartis
Nucala (mepolizumab) - GSK
CDX-0159 - Celldex
Fasenra (benralizumab) - AstraZeneca
Dupixent (dupilumab) - Sanofi, Regeneron
avdoralimab (IPH5401) - Innate
http://www.ncbi.nlm.nih.gov/pubmed/33685605
 
Mar 10, 2021
 
Prev Next